Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Riociguat Discontinuation in CTEPH After BPA
NCT06922240Phase 3Recruiting
- Start
- Mar 2025
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms). Primary endpoint: Change from Baseline in the Cardiac Output at 6 months. Started Mar 2025; status: recruiting.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT06922240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06922240.